Venus Remedies has partnered with Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, to ...

Department of Civil & Environmental Engineering, Louisiana State University, Baton Rouge, Louisiana 70803, United States ...

The agreement authorises Venus Remedies to spearhead the clinical development, registration, and commercialisation of MET-X, ...

Venus Remedies is collaborating with UK-based Infex Therapeutics for the clinical development of MET-X, a ...

The deal grants Venus Remedies the rights to develop, register, and commercialise MET-X, a novel metallo-beta-lactamase (MBL) ...

Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Through this platform, resistance in bacterial samples can be tested within two hours compared to 24-27 hours through other ...

A study of 151 patients with carbapenem-nonsusceptible infections found treatment with imipenem/cilastatin/relebactam was ...

A survey of the province's public hospitals and microbiology labs found the rate of new patients with carbapenemase-producing ...

Antimicrobial resistance (AMR) is a critical global health challenge, requiring early and accurate detection of resistance ...